These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1091 related articles for article (PubMed ID: 26275126)

  • 1. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
    Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor imaging with [
    Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is unenhanced 18F-FDG-PET/CT better than enhanced CT in the detection of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma?
    Wu IS; Hung GU; Chang BL; Liu CK; Chang TH; Lee HS; Chen MK
    Ear Nose Throat J; 2016; 95(4-5):178-84. PubMed ID: 27140019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma.
    Schartinger VH; Dudás J; Url C; Reinold S; Virgolini IJ; Kroiss A; Riechelmann H; Uprimny C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):20-4. PubMed ID: 25227762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of [
    Liu M; Chen X; Ding H; Shu Q; Zheng Y; Chen Y; Cai L
    Mol Imaging Biol; 2024 Aug; 26(4):658-667. PubMed ID: 38627276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A head-to-head comparison of
    Qin C; Liu F; Huang J; Ruan W; Liu Q; Gai Y; Hu F; Jiang D; Hu Y; Yang K; Lan X
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3228-3237. PubMed ID: 33609152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of [
    Zhao L; Pang Y; Zheng H; Han C; Gu J; Sun L; Wu H; Wu S; Lin Q; Chen H
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3606-3617. PubMed ID: 33792760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of [
    Ji M; Ma G; Liu C; Gu B; Du X; Ou X; Xu X; Song S; Yang Z
    Cancer Imaging; 2024 May; 24(1):56. PubMed ID: 38702821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Zheng J; Liu F; Lin K; Zhang L; Huang N; Zheng W; Zhang J; Yao S; Miao W
    Mol Imaging Biol; 2022 Dec; 24(6):973-985. PubMed ID: 35945360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of [
    Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of (18)F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site.
    Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Xuan W; Chicco A; Fowler A
    Radiother Oncol; 2016 Jul; 120(1):87-91. PubMed ID: 27321151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between (68)Ga-DOTA-NOC PET/CT and (18)F-FDG PET/CT in EBV-positive undifferentiated nasopharyngeal carcinoma.
    Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1162-3. PubMed ID: 25680401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 55.